Commonwealth of Pennsylvania Public School Empls Retrmt SYS Cuts Stock Position in CVS Health Corporation $CVS

Commonwealth of Pennsylvania Public School Empls Retrmt SYS lessened its holdings in CVS Health Corporation (NYSE:CVS) by 3.1% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 295,277 shares of the pharmacy operator’s stock after selling 9,294 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in CVS Health were worth $23,433,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. increased its stake in CVS Health by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator’s stock worth $9,579,508,000 after buying an additional 1,824,424 shares in the last quarter. Capital World Investors increased its stake in CVS Health by 2.1% in the 3rd quarter. Capital World Investors now owns 68,382,158 shares of the pharmacy operator’s stock worth $5,155,380,000 after buying an additional 1,419,575 shares in the last quarter. State Street Corp increased its stake in CVS Health by 0.3% in the 3rd quarter. State Street Corp now owns 58,938,286 shares of the pharmacy operator’s stock worth $4,443,357,000 after buying an additional 149,701 shares in the last quarter. Capital International Investors increased its stake in CVS Health by 1.1% in the 3rd quarter. Capital International Investors now owns 26,692,203 shares of the pharmacy operator’s stock worth $2,012,347,000 after buying an additional 302,499 shares in the last quarter. Finally, Invesco Ltd. increased its stake in CVS Health by 3.2% in the 3rd quarter. Invesco Ltd. now owns 24,293,058 shares of the pharmacy operator’s stock worth $1,831,454,000 after buying an additional 760,579 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on CVS shares. Argus increased their price target on CVS Health from $90.00 to $104.00 and gave the stock a “buy” rating in a research note on Thursday, May 14th. The Goldman Sachs Group increased their price target on CVS Health from $95.00 to $97.00 and gave the stock a “buy” rating in a research note on Thursday, February 12th. Robert W. Baird raised their price objective on CVS Health from $92.00 to $94.00 and gave the company an “outperform” rating in a research report on Wednesday, April 15th. Wells Fargo & Company raised their price objective on CVS Health from $102.00 to $103.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Finally, Morgan Stanley raised their price objective on CVS Health from $93.00 to $106.00 and gave the company an “overweight” rating in a research report on Thursday, May 14th. Twenty-two research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $98.88.

Insider Activity

In related news, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the transaction, the executive vice president owned 10,133 shares in the company, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Larry Robbins sold 1,983,538 shares of CVS Health stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total value of $187,345,164.10. Following the completion of the transaction, the director owned 6,213,261 shares of the company’s stock, valued at approximately $586,842,501.45. This represents a 24.20% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 3,441,551 shares of company stock valued at $323,703,977. 0.85% of the stock is currently owned by company insiders.

CVS Health Trading Down 0.0%

Shares of CVS Health stock opened at $90.97 on Monday. The firm has a market cap of $116.06 billion, a price-to-earnings ratio of 40.07, a PEG ratio of 0.89 and a beta of 0.62. The business has a 50-day moving average price of $82.07 and a 200-day moving average price of $79.56. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. CVS Health Corporation has a twelve month low of $58.50 and a twelve month high of $98.43.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. The firm had revenue of $100.43 billion during the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The business’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities research analysts anticipate that CVS Health Corporation will post 7.44 EPS for the current fiscal year.

CVS Health Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were given a $0.665 dividend. The ex-dividend date was Thursday, April 23rd. This represents a $2.66 annualized dividend and a yield of 2.9%. CVS Health’s dividend payout ratio (DPR) is currently 117.18%.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Caremark said it will restore coverage of Eli Lilly’s Zepbound and add Lilly’s new obesity pill to its standard drug plans, a move that could boost CVS’s pharmacy-benefit relevance and improve customer access to GLP-1 medications. CVS brings back coverage for Lilly’s obesity drug Zepbound
• Positive Sentiment: The company announced expanded GLP-1 coverage options, which management framed as improving affordability and access while supporting more sustainable long-term coverage. CVS Caremark Delivers Affordability and Access to GLP-1 Weight Management Medications with Expanded Coverage Options
• Positive Sentiment: CVS Health expanded its collaboration with Salesforce to streamline call center interactions using AI, which could improve service quality and operating efficiency across its member and provider base. CVS Health to Deliver Faster, More Personalized Call Center Care for Millions of Members with Salesforce’s Agentforce Health
• Positive Sentiment: CVS Health also launched Aetna Mental Health On Demand and continued building out digital health capabilities, reinforcing its integrated care strategy. CVS Health Expands Integrated Care With Virtual Mental Health AI And GLP 1
• Neutral Sentiment: CVS received a Newsweek AI Impact Award for prescription-interpretation technology, highlighting innovation in pharmacy workflow and medication safety. CVS Health recognized for technology that improves medication safety and patient care
• Neutral Sentiment: Glenview Capital said CVS remains one of its top holdings, which supports investor confidence but does not by itself change fundamentals. Glenview Capital Keeps CVS Health (CVS) Among Top Holdings

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.